Ensysce Biosciences` PF614-MPAR Enters Final Stage of Phase 1 Study
Ensysce Biosciences, Inc., a clinical-stage biotech company applying transformative chemistry to improve prescription drug safety focused on reducing abuse and overdose, announced the first subjects dosed in the PF614-104 study, ‘A Randomized, Double-blind, Placebo and Active-Controlled, Crossover Study to Evaluate the Oral Abuse Potential of PF614 Compared with oxycodone immediate-release tablets, and Placebo in Non-Dependent Recreational Opioid Users' (ClinicalTrials.gov Identifier: NCT05571345).